Cases & Deals

  • Home
  • Practices
  • AbbVie collaborates with Alvine Pharmaceuticals to develop treatment for celiac disease

Share

AbbVie collaborates with Alvine Pharmaceuticals to develop treatment for celiac disease

May 2013

Client(s) AbbVie Inc.

Jones Day advised AbbVie Inc. in connection with a collaboration with Alvine Pharmaceuticals for the development of a treatment for patients with celiac disease. As part of the collaboration, AbbVie made a $70 million payment to Alvine to secure an exclusive option to acquire, at AbbVie's election, either the assets relating to the program or the outstanding equity of Alvine, in either case following the completion of an ongoing Phase 2b clinical study. If AbbVie exercises its option, AbbVie will also agree to pay a milestone payment to Alvine once an Phase 3 study is initiated with respect to the program.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.